*FDA APPROVES CAMBIUM BIO'S POTENCY ASSAY STRATEGY FOR ELATE OCULAR PHASE 3 CLINICAL TRIALS
*Further company coverage: CMB.AX
* ((Reuters.Briefs@thomsonreuters.com;))
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 18-MAR-202500:51:34 GMT